STAT+: Eli Lilly dives into hair loss treatments with investment in AI startup Absci

Eli Lilly has made a strategic investment in Absci, a startup leveraging artificial intelligence to develop a novel medication aimed at treating hair loss and potentially endometriosis. This move underscores Lilly's commitment to exploring new frontiers in medical treatment, especially in areas with significant unmet needs. By harnessing AI, Absci aims to accelerate the drug discovery process, which could lead to more efficient and innovative treatments. This investment highlights the growing intersection between biotech and AI, signaling a promising future for personalized medicine.